Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Elena Cazzaniga, Valter Torri, Claudio Verusio et al.|Oncotarget|2018Cited by 4
Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.Marina Elena Cazzaniga, Benedetta Pellegrino, Graziella Pinotti et al.|Journal of Clinical Oncology|2017Cited by 2
Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 StudyMarina Elena Cazzaniga, Valter Torri, Maria Rosaria Valerio et al.|The Breast|2017Cited by 0